Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HX301 + temozolomide
- Development stage
- Phase 2
- Lead developer
- Hanx Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HX301 + temozolomide is an investigational combination therapy being studied for the treatment of high-grade glioma and other brain tumors. Temozolomide is an oral alkylating agent used as chemotherapy for certain types of brain cancer, including glioblastoma multiforme and anaplastic astrocytoma. It works by methylating DNA bases in tumor cells, leading to DNA damage and apoptosis[1][5][8]. HX301 is a novel investigational drug whose specific mechanism of action has not been disclosed publicly but is under evaluation in clinical trials in combination with temozolomide to assess safety and preliminary antitumor activity[3]. The combination aims to improve outcomes for patients with aggressive brain tumors.
- Brand names
- Temodal
- Other names
- HX301HX-301HX 301
02
Targets
DNA
Beyond the preview
Go deeper on HX301 + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HX301 + temozolomide.